论文部分内容阅读
目的:探讨骨桥蛋白在不同分期糖尿病肾病患者肾组织的表达及其临床意义。方法:用免疫组化方法检测无糖尿病肾病组(N=20)、早期糖尿病肾病组(n=20)、临床糖尿病肾病组(n=20)肾组织骨桥蛋白的表达情况。结果:在不同分期糖尿病肾病组的骨桥蛋白表达不同,无糖尿病肾病组骨桥蛋白表达最低,临床糖尿病肾病组骨桥蛋白表达最高。结论:骨桥蛋白可能是糖尿病肾病的重要发病因素之一,抑制糖尿病患者肾脏骨桥蛋白的表达,可能延缓糖尿病肾病的进展。
Objective: To investigate the expression of osteopontin in renal tissues of diabetic nephropathy patients with different stages and its clinical significance. Methods: Immunohistochemistry was used to detect the expression of osteopontin in non-diabetic nephropathy (N = 20), early diabetic nephropathy (n = 20) and clinical diabetic nephropathy (n = 20). Results: The expression of osteopontin in diabetic nephropathy group with different stages had the lowest osteopontin expression in diabetic nephropathy group and the highest osteopontin expression in clinical diabetic nephropathy group. CONCLUSION: Osteopontin may be one of the important pathogenetic factors of diabetic nephropathy. Inhibition of osteopontin expression in diabetic nephropathy may delay the progression of diabetic nephropathy.